Retatrutide (GLP-3): The Triple Agonist Peptide

Retatrutide (GLP-3): The Triple Agonist Peptide — A Research Overview

Retatrutide is one of the most closely watched compounds in current metabolic research. A triple agonist of three incretin and glucagon-related receptors simultaneously, it represents a pharmacological approach that goes substantially further than first-generation GLP-1 receptor agonists. For researchers studying metabolic regulation, energy homeostasis, and adipose tissue biology, retatrutide offers a mechanistically distinct and increasingly well-characterized research subject.

What Is Retatrutide?

Retatrutide — also referred to as LY3437943 by its developer Eli Lilly — is a synthetic peptide designed to simultaneously agonize three receptors:

1. GLP-1R — Glucagon-like peptide-1 receptor
2. GIPR — Glucose-dependent insulinotropic polypeptide receptor
3. GcgR — Glucagon receptor

This triple receptor agonism is what distinguishes retatrutide from its predecessors in the GLP class. Semaglutide (Ozempic/Wegovy) is a GLP-1 monoagonist. Tirzepatide (Mounjaro) is a GLP-1/GIP dual agonist. Retatrutide adds glucagon receptor agonism to that combination — a third mechanism with distinct metabolic implications, particularly for energy expenditure.

The informal designation "GLP-3" used in the research community is not an official receptor nomenclature but rather a shorthand reflecting retatrutide's position as the third generation of GLP-class metabolic peptides.

Molecular specifications:

Developer Code: LY3437943

Receptor Targets: GLP-1R, GIPR, GcgR (triple agonist)

Molecular Weight: ~4,883 Da

Half-life (in vivo): ~6 days (designed for weekly dosing in clinical studies)

Form: Lyophilized powder

Purity: ≥98–99%

The Three Receptors: What Each One Does 

GLP-1R (Glucagon-Like Peptide-1 Receptor)

GLP-1 is an incretin hormone secreted by L-cells in the small intestine in response to food intake. Its receptor (GLP-1R) is expressed in the pancreas, brain, gastrointestinal tract, and heart, among other tissues.

GLP-1R agonism produces:

• Glucose-dependent insulin secretion (insulin released only when glucose is elevated)
• Suppression of glucagon secretion
• Delayed gastric emptying (contributing to satiety)
• Reduced appetite via central nervous system signalling in hypothalamic nuclei
• Potential cardiovascular protection (observed in clinical trials of GLP-1 agonist drugs)

This receptor is the foundation of the entire GLP drug class, from exenatide to semaglutide.

GIPR (Glucose-Dependent Insulinotropic Polypeptide Receptor)

GIP is the other major incretin hormone, secreted by K-cells in the duodenum. Like GLP-1, it enhances glucose-dependent insulin secretion. For years, GIPR agonism was considered a less useful target because GIP's insulinotropic effect is blunted in type 2 diabetes.

The addition of GIPR agonism in tirzepatide — and subsequently retatrutide — was initially counterintuitive but has produced markedly superior metabolic outcomes in clinical research compared to GLP-1 monoagonism alone. The mechanism of this synergy is an active area of investigation. Hypotheses include GIPR-mediated enhancement of GLP-1R sensitivity and independent adipose tissue effects of GIPR agonism.

GIPR is also expressed in bone tissue and the central nervous system, giving it research relevance beyond pure metabolic biology.

GcgR (Glucagon Receptor)

Glucagon is the counter-regulatory hormone to insulin — it raises blood glucose by stimulating hepatic glucose production and glycogenolysis. Adding glucagon receptor agonism to an already insulin-sensitizing compound might appear contradictory.

The rationale is energy expenditure. Glucagon receptor agonism increases:

• Basal metabolic rate
• Thermogenesis (heat production from brown adipose tissue)
• Hepatic fat oxidation
• Fatty acid oxidation in skeletal muscle

The key insight is that when glucagon receptor agonism is combined with GLP-1R agonism (which counters glucagon's glucose-raising effects), the net glycaemic outcome remains favourable while the metabolic-rate and fat-oxidation benefits of glucagon are preserved. This combination is what gives retatrutide its distinctive energy expenditure profile in research models.

Preclinical Research

Preclinical studies with retatrutide and related triple agonists have examined outcomes in diet-induced obesity models, type 2 diabetes rodent models, and non-alcoholic steatohepatitis (NASH) models.

Key findings from animal studies:

• Superior body weight reduction compared to GLP-1 monoagonists in diet-induced obese rodent models
• Significant reduction in hepatic fat content in NASH models, suggesting relevance for metabolic liver disease research
• Improvements in lipid profiles (triglycerides, LDL cholesterol) beyond what was observed with GLP-1 monoagonism alone
• Evidence of increased energy expenditure — supporting the glucagon receptor-mediated thermogenesis hypothesis

Clinical Research Overview

Retatrutide has progressed into human clinical trials managed by Eli Lilly, representing a level of regulatory engagement unusual for research peptides. Key findings from published Phase 1 and Phase 2 trial data:

Phase 1 (2022): Dose-escalation studies in adults with obesity and type 2 diabetes established initial safety and pharmacokinetics data. The compound's half-life supported weekly administration in clinical dosing — a property relevant to the study drug design.

Phase 2 (2023 — published in New England Journal of Medicine): A landmark 48-week randomized controlled trial enrolled 338 adults with obesity (no diabetes). At the highest dose studied, subjects receiving retatrutide lost an average of approximately 24% of body weight — surpassing outcomes reported in comparable Phase 2 trials of semaglutide and tirzepatide at equivalent timepoints. This data placed retatrutide among the most efficacious metabolic compounds yet studied in controlled clinical trials.

NASH Research: Retatrutide has also entered trials examining non-alcoholic steatohepatitis outcomes, reflecting the recognized connection between obesity-related metabolic dysfunction and liver disease.

As of the time of writing, retatrutide remains an investigational compound. It has not received regulatory approval from Health Canada, the FDA, or any other agency.

Why Retatrutide Is Studied Alongside Other Metabolic Peptides

Researchers studying metabolic biology frequently examine retatrutide in comparison to or alongside:

Tesamorelin — A GHRH analogue that specifically reduces visceral adipose tissue. Retatrutide and tesamorelin target fat loss via entirely different mechanisms (incretin/glucagon axis vs. growth hormone axis), making them complementary subjects in adipose tissue research. 

Semaglutide / GLP-1 monoagonists — Retatrutide is frequently benchmarked against semaglutide in metabolic model research as a direct within-class comparison for the incremental effect of adding GIP and glucagon agonism.

MOTS-c — A mitochondrial peptide with distinct energy metabolism research relevance. Researchers interested in energy homeostasis at a cellular level may examine MOTS-c and retatrutide in complementary but mechanistically different frameworks.

Reconstitution Method

Retatrutide in research-grade lyophilized form is reconstituted using bacteriostatic water, following the same general protocol as other lyophilized research peptides.

Protocol:

1. Wipe the tops of both the retatrutide vial and BAC water vial with an alcohol wipe. Allow to air dry.
2. Draw the required volume of BAC water into an insulin syringe.
3. Insert the needle through the retatrutide vial stopper at an angle.
4. Release BAC water slowly against the inner wall. Do not inject directly onto the powder.
5. Swirl gently — do not shake. Allow up to 2 minutes for complete dissolution.
6. The solution should be clear and colourless.

Concentration reference:

BAC Water Added	Retatrutide Amount	Concentration
1ml	2mg	2mg/ml
2ml	5mg	2.5mg/ml
1ml	5mg	5mg/ml

For the full reconstitution and concentration calculation guide, see: How to Reconstitute Peptides with BAC Water

Storage

 

State	Condition	Estimated Stability
Lyophilized powder	-20°C	Up to 24 months
Lyophilized powder	4°C	Up to 3 months
Reconstituted solution	4°C	28 days
Reconstituted solution	Room temperature	24 hours max

Protect from light and avoid freeze-thaw cycles of reconstituted solution.

Sourcing Retatrutide in Canada

Retatrutide has attracted significant research interest since the publication of its Phase 2 trial data. This demand has unfortunately driven a significant increase in low-quality supply in the research peptide market. Researchers sourcing retatrutide should apply rigorous criteria:

• Independent third-party COA from a named analytical laboratory — not self-reported purity
• HPLC or Mass Spectrometry verification confirming ≥98% purity and correct molecular identity
• Batch-specific testing — not a generic COA applied across multiple batches
• Canadian-based supplier for cold-chain integrity and elimination of customs risk

View Our COA-Verified Retatrutide — Ships Same Day from Canada

Frequently Asked Questions

What does "GLP-3" mean?

It is an informal designation in the research community reflecting retatrutide's position as the third generation of GLP-class metabolic peptides (after GLP-1 monoagonists and GLP-1/GIP dual agonists). It does not refer to a third GLP receptor — the official name for such a receptor does not exist in current pharmacology nomenclature.

How is retatrutide different from semaglutide?

Semaglutide is a GLP-1 receptor monoagonist. Retatrutide additionally agonizes the GIP receptor and the glucagon receptor, making it a triple agonist with distinct effects on energy expenditure and adipose tissue beyond what GLP-1 agonism alone produces.

Has retatrutide been approved for human use?

No. As of the writing of this article, retatrutide remains an investigational compound in clinical trials. It has not received regulatory approval from Health Canada, the FDA, or any other regulatory agency.

Is retatrutide available in Canada for research?

Yes. Research-grade retatrutide is available for purchase by qualified researchers in Canada. It is sold for in vitro and laboratory research use only.

Summary

Retatrutide represents the current frontier of incretin-based metabolic research. Its triple receptor agonism — targeting GLP-1R, GIPR, and GcgR simultaneously — produces a metabolic profile that surpasses earlier GLP-class compounds in published clinical research. For Canadian researchers studying obesity biology, metabolic syndrome, NASH, and energy homeostasis, retatrutide is a mechanistically rich and actively investigated research subject.

[Shop Retatrutide (GLP-3)] [Shop BAC Water]

⚠️ Disclaimer: Retatrutide is sold by Emerald Peptides strictly for in vitro research and laboratory use. It is not approved by Health Canada or any regulatory agency for human or veterinary use. It is an investigational compound. By purchasing, the buyer confirms they are a qualified researcher using this compound in a legitimate research setting.